MDS Virtual Congress 2020 » Parkinson’s Disease: Pharmacology and Therapy

Meeting: MDS Virtual Congress 2020

12-month therapeutic evaluation of l-dopa carbidopa ascorbic acid solution (LCAS) in a cohort of Advanced Parkinson’s disease in a North-Indian tertiary care hospital

K. Shukla, N. Sawal (Chandigarh, India)

A Case of Improved Psychotic Depression and Motor Symptoms in Parkinson’s Disease following Electroconvulsive Therapy (ECT)

S. Ramesh, J. Ratliff (Philadelphia, PA, USA)

A monocentric experience of Apomorphine pump follow-up on PD patients: The Optipump Cohort

C. Virbel-Fleischman, M. Houot, Y. Rétory, S. Hardy, J.C Corvol, D. Grabli (Gentilly, France)

A Parkinson’s disease dog providing therapeutic intervention in Parkinson’s disease

C. Buckley, B. O'Callaghan, J. Dowler, N. Austin, E. Reynolds, M. Lowery, T. Lynch (Dublin 7, Ireland)

A pilot study on the efficacy, tolerability and safety of safinamide in elderly Parkinson’s disease patients

D. Rinaldi, M. Sforza, E. Bianchini, S. Galli, F.E Pontieri (Rome, Italy)

A pilot study on the shift from rasagiline to safinamide in fluctuating Parkinson’s disease patients

M.S Sforza, F.E Pontieri, D.R Rinaldi, E.B Bianchini (Rome, Italy)

Accounting for unmeasured confounders in treatment response: a comparison of levodopa versus non-levodopa dopaminergic drugs

M. Javidnia, W. Artman, J. Jones, A. Ertefaie, C. Venuto (Rochester, NY, USA)

All-cause mortality in pimavanserin and atypical antipsychotic users with Parkinson’s disease in Medicare

A. Mosholder, Y. Ma, S. Akhtar, G. Podskalny, Y. Wei, J. Liao, Y. Feng, H. Lyu, M. Wernecke, K. Leishear, L. Nelson, T. MaCurdy, J. Kelman, D. Graham (Silver Spring, MD, USA)

An Analysis of Parkinson’s Disease Medication Treatment Patterns among Medicaid Patients

M. Johnsrud, K. Richards, R. Sasane, M. Leoni, S. Arcona (Austin, TX, USA)

Andrograholide protect microglial activation via inhibiting mitochondrial ROS generation and NLRP3 inflammasome activation in in-vitro and in-vivo model of Parkinson’s disease

S. Ahmed, V. Naidu (Kamrup, India)

Anti-parkinson effect of natural L-DOPA containing drug Mucuna pruriens against the rotenone induced rat model of Parkinson’s disease

V. Kumar, F. Anwar (Allahabad, India)

Anticholinergic Burden in Parkinson’s Disease Patients in India – A Hospital Based Study

A. Saini, R. Rajan, R. Anandapadmanabhan, V. Venogopalan, A. Gupta, B. Verma, N. Choudhary, R. Bhatia, M. Singh, A. Srivastava, P. Srivastava (New Delhi, India)

Apomorphine subcutaneous infusion reduces dopaminergic dosage whilst maintaining motor benefits in Parkinson’s disease: A prospective analysis of Thai Apomorphine Registry

O. Phokaewvarangkul, K. Boonpang, R. Bhidayasiri (Bangkok, Thailand)

Beta-adrenoreceptor medications and risk of Parkinson’s disease

X. Li, L. Wang, Y. Zhang (Guangzhou, China)

Blood hexokinase reduction in de novo Parkinson’s disease and remodeling of glycolytic energy homeostasis with L-DOPA/Istradefylline combination therapy

N. Kanzato, K. Nakachi, S. Mochizuki, (Okinawa, Japan)

Calcitriol Treatment Attenuates Dopaminergic Neurodegeneration in Mice Model of Parkinson’s Disease

JJ. Hu, T. Wang (Wuhan, China)

Can we customize tune for asymmetric tremor with differentiated Deep brain stimulation frequencies?

G. Baille, A. Kreisler, G. Touzet, L. Defebvre, D. Devos, C. Moreau (Lille, France)

Ceftriaxone improves motor function in a rat hemi-parkinsonian model: Potential to delay bilateral progression of motor deficits in Parkinson’s disease

E. Kasanga, C. McElroy, M. Salvatore (Fort Worth, TX, USA)

Characterization of novel alpha-synuclein aggregation model of Parkinson’s disease

A. Singh, S. Reunanen, A. Panhelainen, M. Voutilainen (Helsinki, Finland)

Characterization of the pattern of daily motor fluctuations in Parkinson’s disease patients based on home diaries

R. Hauser, W. Poewe, J. Ferreira, A. Lees, G. Liang, M. Fonseca, D. Magalhães, J.F Rocha, P. Soares-da-Silva (Tampa, FL, USA)

Claims Data Analysis of Parkinson’s Disease Medication Utilization

M. Frazer, C. Blauer-Peterson, R. Sasane, S. Arcona, Y. Fang, R. Halpern (Eden Prairie, MN, USA)

Combined therapy VS only levodopa therapy in a 5-years follow up cohort

C. Borrue-Fernandez, J. Alvarez -Alberca (San Sebastian Reyes, Spain)

Comparing the effects of rosemary and selegiline on behavioral symptoms of Parkinson’s animal model in mice

M. Modaresi (Isfahan, Islamic Republic of Iran)

Comparison of the effect of hydroalcoholic extract of olive leaf and levodopa on reducing parkinson’s symptoms in animal model

M. Modaresi (Isfahan, Islamic Republic of Iran)

Complex patterns of dyskinesias in patients chronically treated with enterally administered levodopa/carbidopa gel

A. Franco Salinas, L. Ruiz-escribano Menchén, J. Cabello, M. Gallardo Alcañiz, J. Vaamonde Gamo, R. Ibáñez Alonso, A. Camacho Nieto (Ciudad Real, Spain)

Correlation Between Dyskinesia and Quality of Life at Baseline and After 12 months of Treatment with LCIG in Patients with Advanced Parkinson’s Disease

J. L Aldred, F. E Pontieri, L. Bergmann, T. Gao, P. Kukreja, P. Bourgeois, N. Kovács (Spokane, WA, USA)

Correlation between location of active contacts and weight gain after subthalamic nucleus deep brain stimulation in Parkinson’s disease

K. Eguchi, I. Yabe, S. Shirai, M. Matsushima, T. Kano, K. Yamazaki, S. Hamauchi, T. Sasamori, K. Hirata, T. Seki, M. Kitagawa, M. Otsuki, T. Shiga, K. Hokin, H. Sasaki (Sapporo, Japan)

Deep Brain Stimulation as the Only Advanced Therapy Available in the Dominican Rebublic, Report ot Two Cases in Centro Cardio Neuro Oftalmologico Y Transplante (Cecanot)

R. Cruz, A.A Perez (Santo Domingo, Dominican Republic)

Deep brain stimulation lead position impact on parkinsonian non-motor symptoms

J. Bardoň, S. Kurčová, M. Chudáčková, P. Otruba, D. Krahulík, M. Nevrlý, P. Kaňovský, J. Zapletalová, J. Valošek, P. Hluštík (Olomouc, Czech Republic)

Distribution of intranasal hNSCs in a mouse model of MPTP-induced Parkinson’s disease

F. Wang, Y.T Zhang, S.Z Wei, C. Ren, C.F Liu (Suzhou, China)

Effect of opicapone and entacapone on daily pattern of motor fluctuations in Parkinson’s disease patients

A. Lees, O. Rascol, J. Ferreira, O. Klepitskaya, M. Fonseca, D. Magalhães, J.F Rocha, P. Soares-da-Silva (London, United Kingdom)

Effect of opicapone and entacapone on early morning-OFF pattern in Parkinson’s disease patients with motor fluctuations

A. Videnovic, W. Poewe, A. Lees, J. Ferreira, O. Klepitskaya, R. Loureiro, D. Magalhães, J.F Rocha, P. Soares-da-Silva (Boston, MA, USA)

Effect of opicapone and entacapone on levodopa short duration response

P. LeWitt, J. Ferreira, G. Ebersbach, E. Tolosa, G. Liang, R. Loureiro, D. Magalhães, J.F Rocha, P. Soares-da-Silva (Detroit, MI, USA)

Effect of the MAO-B inhibitor and glutamate modulator safinamide on depressive symptoms in three Parkinson’s disease patients

W.E Hofmann (Aschaffenburg, Germany)

Effectiveness and Tolerability of Mirabegron and Behavioral Therapy in Patients with Parkinson’s Disease and Overactive Bladder: A Prospective, Randomized, Placebo-Controlled Pilot Study

S. Ray, D. Burdick, P. Agarwal, A. Madan (Kirkland, WA, USA)

Effectiveness of Carbidopa/Levodopa Enteral Suspension (CLES) in Advanced Parkinson’s Disease (APD) Patients with Moderate to Severe Fatigue: Sub-group Analysis from PROviDE study

S. Isaacson, J. Aldred, D. Cella, P. Kandukuri, N. Gupta, Y. Jalundhwala, P. Kukreja, I. Pan, R. Pahwa (North Chicago, IL, USA)

Effectiveness of dopaminergic drugs on motor symptoms in Parkinson’s disease patients with deep brain stimulation of subthalamic nucleus

L.K SAHOO, D. Batra, N. Kamble, R. Yadav, D. S, P. Pal (Bangalore, India)

Effectiveness of onabotulinumtoxinA on reduction of rest tremor in Parkinson’s disease: A pilot study

D. Roque, D. Drazheva, N. Browner, M. Sklerov, M. Collins (Chapel Hill, NC, USA)

Effects of a community-based adapted boxing program on physical capacity and quality of life in individuals with Parkinson disease over a 12 month period

S. Benoit, E. Riesco, A. Tanguay (Sherbrooke, QC, Canada)

Effects of a next-generation neurotrophic compound in a toxin model of Parkinson’s disease

T. Viljakainen, M. Saarma, M. Voutilainen (Helsinki, Finland)

Effects of onabotulinum toxin A on balance and gait in Parkinson’s disease with foot dystonia: A case series study

P. Huang, YY. Li, P. Huang, Q. Xiao, Y. Wang, S. Chen, S.D Chen, J. Liu, Y.W Wu (Shanghai, China)

Efficacy and Safety of High Doses of Safinamide in Advanced Parkinson’s Disease Patients in a Real-World Experience

F. Rodríguez Jorge, A. Beltrán Corbellini, P. Parra Díaz, J.L Chico García, J. Pagonabarraga Mora, B. Baena Álvarez, I. Parées Moreno, J.L López-Sendón, P. Pérez Torre, J.C Martínez Castrillo, A. Alonso Cánovas (Madrid, Spain)

Efficacy and safety of istradefylline in Parkinson’s disease patients with postural abnormality: Results from a multicenter, open-label study in Japan

M. Takahashi, T. Shimokawa, J. Koh, T. Takeshima, H. Yamashita, Y. Kajimoto, A. Mori, H. Ito (Osaka, Japan)

Efficacy and safety of levodopa-carbidopa intestinal gel (LCIG) for advanced Parkinson’s disease: a Turkish single-centre experience

Y. Sucullu Karadag (Ankara, Turkey)

Efficacy and Safety of Opicapone in Parkinson’s Disease Patients According to Duration of Motor Fluctuations: Post-Hoc Analysis of BIPARK-I and II

G. Ebersbach, O. Rascol, J. Ferreira, R. Costa, J.F Rocha, D. Magalhães, P. Soares-da-Silva (Beelitz, Germany)

Efficacy and safety/tolerability of opicapone in catechol-O-methyltransferase inhibitor-naïve Parkinson’s disease patients recently diagnosed with motor fluctuations

A. Lees, J. Ferreira, W. Poewe, H. Gama, D. Magalhães, J.F Rocha, P. Soares-da-Silva (London, United Kingdom)

Efficacy and security starting safinamide treatment with 100 mg/day in Parkinson’s disease

N. Foncea (Galdakao, Spain)

Efficacy and tolerability of opicapone in Parkinson´s disease in usual clinical practice

V. Gomez-Mayordomo, F. Alonso-Frech, E. Lopez-Valdes, R. Garcia-Ramos, M. Catalan-Alonso (Madrid, Spain)

Efficacy of opicapone compared to entacapone in catechol-O-methyltransferase inhibitor-naïve Parkinson’s disease patients recently diagnosed with motor fluctuations: A post-hoc conservative analysis

J. Ferreira, A. Lees, G. Ebersbach, A.T Santos, D. Magalhães, J.F Rocha, P. Soares-da-Silva (Lisbon, Portugal)

Efficacy of opicapone in different levodopa-containing treatment regimens in Parkinson’s disease patients with motor fluctuations

A. Antonini, G. Ebersbach, O. Rascol, F. Ikedo, D. Magalhães, J.F Rocha, P. Soares-da-Silva (Padova, Italy)

Epidemiology of Impulse Control Disorders and Association with Dopamine Agonist Exposure in the United States Military

A. Garrett, S. Bazaco, S. Clausen, A. Oetting, S. Stahlman (San Diego, CA, USA)

Euphoria-inducing lead contacts: mapping of image and electrophysiology in Parkinson’s disease

Y.C Chen, C.H Yeh, P.H Tu, P.L Chen, H. Wu, M.K Yang, C.C Chen (Taoyuan, Taiwan)

Evaluation of Advanced Parkinson’s Patients Using Levodopa Carbidopa Instestinal Gel: Results of the Aegean Region of Turkey

O. Yilmaz Kusbeci, A. Acarer, B. Donmez Colakoglu, I. Inci, R. Cakmur, A. Akyol, Z. Colakoglu (Izmir, Turkey)

Evidence towards the clinical benefits of using directional leads in Deep Brain Stimulation for movement disorders: Consecutive case series

M. Contreras, J. Saavedra, J. Espinoza, G. Arango, T. Lopez (La Serena, Chile)

Frequency and risk factors of dopamine agonist-induced peripheral edema in patients with Parkinson’s disease

S. Bostan, N. Durmaz Çelik, S. Özkan (Eskisehir, Turkey)

Gut Microbiote Distinctive Features and Microbiota-Metabolome Profile in Parkinson’s Disease: Focus on Levodopa and LCIG

M. Melis, V. Oppo, S. Vascellari, M. Fabbri, M. Sarchioto, D. Murgia, M. Zibetti, L. Lopiano, A. Manzin, G. Cossu (Cagliari, Italy)

High levodopa plasma concentration in the acute levodopa challenge test predicts levodopa-induced dyskinesia in Parkinson’s disease

T. Shiraishi, N. Nishikawa, Y. Mukai, Y. Takahashi (Kodaira-shi, Tokyo, Japan)

High Satisfaction and Improved Quality of Life with Rock Steady Boxing in Parkinson’s Disease

D. Larson, D. Bega, M. Rafferty, C. Yeh (Chicago, IL, USA)

Identification and characterization of anti-prionic compounds that disassemble αSyn prions as a novel therapeutic approach for synucleinopathies

D. Willbold, M. Sevenich, W. Hoyer, J. Mohrlüder, A. Willuweit (Jülich, Germany)

Impact of dopamine 2/3 receptor agonists on the phenomenology of L-DOPA-induced dyskinesia in patients with Parkinson’s disease

S. Grigoriou, S. Christiansson, P. Odin, M.A Cenci (Lund, Sweden)

Indication and long-term outcome of device-aided therapies in advanced Parkinson’s disease

M. Shiraishi, F. Maki, M. Kato, Y. Morosawa, I. Takumi, K. Isahaya, N. Sasaki, Y. Hasegawa (Kawasaki, Japan)

Inhaled levodopa (LD) as a treatment for Parkinson’s disease (PD) patients in an emergency setting

S. Miri, S. Nakano, A. Carwin, M. Anjum, Y. Torres-Yaghi, F. Amjad, F. Pagan (Washington, DC, USA)

Levodopa and dopamine agonists dosage changes after Opicapone introduction

N. Caballol, A. Planas-Ballvé, A. Ávila (Sant Joan Despí, Spain)

Levodopa Dose Equivalency for Opicapone and Safinamide

J.C Martinez Castrillo, I. Parees Moreno, G. Sanchez Diez, E. Natera Villalba, A. Beltran Corbellini, A. García Plata, A. Alonso Cánovas (Madrid, Spain)

Levodopa induced changes of tongue body movements during speech production

T. Thies, D. Mücke, R. Dano, M.. Barbe (Cologne, Germany)

Low dose Cabergoline for freezing of gait in advanced Parkinson’s disease – you can have your cake and eat it too!

N. Sharma, A. Kumari, N. Sawal, H. Singh, K. Shukla (Chandigarh, India)

Maintenance of safinamide 100 mg daily long-term

N. FONCEA (Galdakao, Spain)

Management of parkinsonian patients with long-term DBS and incomplete control of symptoms

I. Reuter (Giessen, Germany)

Monitoring electrophysiological recordings in patients with LCIJ therapy

D. Gunal, H. Ozden, S. Irmak, K. Uluc (Istanbul, Turkey)

Motor subtype change between OFF and ON periods in patients with Parkinson’s disease

O. Esquivel-Zapata, A. Abundes-Corona, F. Herrera-Rodriguez, O. Cardenas-Saenz, E. Escobar-Valdivia, Y. Ríos-Solís, H. Tellez-Lucero, A. Cervantes-Arriaga, M. Rodriguez-Violante (Mexico, Mexico)

Neuroprotective and neuromodulatory properties of Olea purpurea leaf extract in MPTP intoxicated Parkinsonian rat model

A. Singh, T. Yadav, A. Pandey (Allahabad, India)

New compound increasing glucocerebrosidase activity on primary cell cultures obtained from patients with GBA-associated Parkinson’s disease

M. Nikolaev, A. Kopytova, K. Senkevich, G. Baydakova, I. Miliukhina, E. Zakharova, G. Rychkov, A. Cheblokov, F. Ibatullin, S. Pchelina, A. Emelyanov (Gatchina, Russian Federation)

Non-pharmacological Treatment for Parkinson’s Disease Patients with Depression: A Meta-analysis of Repetitive Transcranial Magnetic Stimulation and Cognitive-Behavioral Treatment

J.N Chen, P.K He, Y.H Zhang, YY. Gao, Y.H Qiu, Y. Li, Q.X Zhang, L.M Wang, J.H Zhao, K. Nie, L.J Wang (Guangzhou, China)

Noninvasive brain stimulation to treat hypokinetic dysarthria in PD: A sham stimulation-controlled trial

I. Rektorova, L. Brabenec, P. Klobusiakova, M. Kostalova (Brno, Czech Republic)

Novel walker attachment for gait dysfunction in Parkinson’s disease: Case report

C. Gill, P. Schmitt, J. Karl, L. Verhagen Metman (Chicago, IL, USA)

Onset of Drug-Related Adverse Events in Parkinson’s Disease Patients with Motor Fluctuations Treated with Opicapone in Clinical Practice: OPTIPARK Post-Hoc Analysis

A. Lees, H. Reichmann, J.F Rocha, D. Magalhães, P. Soares-da-Silva (London, United Kingdom)

Opicapone and entacapone as add-on therapy to the treatment of infusions of levodopa-carbidopa intestinal gel in patients with advanced Parkinson’s disease

J.C Martinez Castrillo, I. Parees Moreno, G. Sanchez Diez, A. Alonso Cánovas (Madrid, Spain)

Opicapone as First-Line Adjunctive Levodopa Treatment in Parkinson’s Disease Patients with Motor Fluctuations: Findings from BIPARK-I and II Combined Post-Hoc Analysis

J. Ferreira, W. Poewe, A. Antonini, H. Gama, J.F Rocha, D. Magalhães, P. Soares-da-Silva (Lisbon, Portugal)

Opicapone in Clinical Practice in Parkinson’s Disease Patients with Motor Fluctuations: Findings from the OPTIPARK Study

H. Reichmann, A. Lees, J.F Rocha, D. Magalhães, P. Soares-da-Silva (Dresden, Germany)

Opicapone in fluctuating Parkinson’s disease: The daily clinical practice

L. Armengou Garcia, G. Martí-Andrés, R. Valentí Azcárate, I. Esparragosa Vázquez, C. Toledano Illán, R. Villino Boquete, R. Luquin (Pamplona, Spain)

Opicapone in Parkinson’s disease – a centre’s real-life experience

F. Carvalho, J. Silva, J. Araújo, M. Rodrigues (Braga, Portugal)

Opicapone management: A 2-year follow up real- life practice study

M. Mata, C. Borrue, M. Almarcha (Madrid, Spain)

Opicapone study in daily clinical practice. OPRA study

J. Abril Jaramillo, J. Rodriguez, H. Perez (Sevilla, Spain)

Opicapone’s added benefit as a first-line adjunctive therapy to levodopa and when used promptly in the motor fluctuations spectrum of Parkinson’s disease: a post-hoc analysis of BIPARK-I and II

G. Ebersbach, J. Ferreira, A. Antonini, A.T Santos, D. Magalhães, J.F Rocha, P. Soares-da-Silva (Beelitz, Germany)

Outcome Profiles in Advanced Parkinson’s Disease Patients Treated With Long-Term Levodopa-Carbidopa Intestinal Gel in a Routine Clinical Practice: Analysis From the COSMOS Study

A. Fasano, R. García-Ramos, T. Gurevich, R. Jech, S. Femia, J. Parra, M. Simu (Toronto, ON, Canada)

Patients’ Perceptions of Herbal Medicine for Parkinson’s disease: Thai Perspectives on Cannabis and Mucuna Pruriens

T. Boonmongkol, O. Phokaewvarangkul, R. Bhidayasiri (Bangkok, Thailand)

Pharmacokinetics of Levodopa in patients with Parkinson’s disease: Efforts toward a predictive model

N. Nishikawa, H. Iwaki, T. Shiraishi, Y. Mukai, Y. Takahashi, N. Hattori (Kodaira, Japan)

Physiologically-based pharmacokinetic modeling of nilotinib to determine serum, cerebrospinal fluid, and brain exposures

C. Venuto, T. Simuni, B. Fiske, C. Coffey, H. Matthews, R. Wyse, P. Brundin, D. Simon, M. Schwarzschild, D. Weiner, J. Adams, L. Trusso, M. Kostrzebski, T. Ward, G. Rafaloff, K. Merchant (Rochester, NY, USA)

Pill burden reduction in patients with advanced Parkinson’s disease: Comparative effectiveness of carbidopa/levodopa enteral suspension and Deep brain stimulation

M. Soileau, F. Pagan, A. Fasano, R. Rodriguez-Cruz, M. Oh, P. Kandukuri, Y. Jalundhwala, Y. Bao, P. Kukreja, M. Siddiqui (Georgetown, TX, USA)

Poly-ADP-ribose polymerase 1 modulates mitochondrial fission via LRRK2 in a rotenone-induced Parkinson’s disease model

L. Bu, Y. Lu, Y. Liang, Y. Chen, S. Peng (Guangzhou, China)

Positive Correlations Between Quality of Life and Sleep Dysfunction in Advanced Parkinson’s Disease Patients Prior to and After 12 Months of Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis From the DUOGLOBE Study

K.R Chaudhuri, J. Boyd, E. Cubo, I. Malaty, F. Pontieri, M. Simu, L. Bergmann, T. Gao, Y. Jalundhwala, P. Kukreja, J. Aldred (London, United Kingdom)

Predicting the influence of deep brain stimulation on Parkinson’s disease gait freezing

O. Gavriliuc, S. Paschen, A. Andrusca, C. Schlenstedt, G. Deuschl (Chisinau, Republic of Moldova)

Quantitative study of T-type Ca2+ channels in the subthalamic nucleus neurons towards Parkinson’s disease

C. Mahapatra (Mumbai, India)

Real-World Data on the Use of Levodopa-Carbidopa Intestinal Gel in Patients with Advanced Parkinson’s Disease who are Treated with Deep Brain Stimulation: The PD-DUAL Study

J. Aldred, F. Amjad, A. Johnson, P. Kukreja, I. Malaty, S. Parashos, J. Siddiqui, M. Siddiqui, J. Zamudio, S. Thakkar (Spokane, WA, USA)

Refining Knowledge on the Treatment of Pisa Syndrome with Botulinum Toxin

C.A Artusi, F. Marchet, U. Dimanico, C. Zanella, M. Zibetti, A. Merola, G. Massazza, L. Lopiano (Torino, Italy)

Sensor-Based Gait Measurements Predict Subthalamic Deep Brain Stimulation Frequency in Parkinson’s Disease Patients – A Proof of Concept Study

J. Watts, A. Khojandi, O. Shylo, R. Ramdhani (Knoxville, TN, USA)

Spontaneous smoking cessation in a parkinsonian patient treated with apomorphine pump

M. Auffret, C. Geny, A. Lees, M. Vérin (Rennes, France)

Super-Responders to Opicapone Adjunct Treatment to Levodopa in Parkinson’s Disease Patients with Motor Fluctuations: Combined Post-Hoc Analysis of BIPARK-I and II

A. Antonini, W. Poewe, J. Ferreira, G. Ebersbach, H. Gama, J.F Rocha, D. Magalhães, P. Soares-da-Silva (Padova, Italy)

Sustained Improvement in Freezing of Gait (FOG) and Treatment Satisfaction at 12 months After Initiation of Carbidopa/Levodopa Enteral Suspension (CLES) in Advanced Parkinson’s Disease (APD) Patients in USA: Interim Results from the PROviDE Study

R. Pahwa, S. Isaacson, B. Bluett, P. Kandukuri, N. Gupta, Y. Jalundhwala, P. Kukreja, I. Pan, J. Aldred (North Chicago, IL, USA)

The influence of ANNK1/DRD2 haplotypes on the onset of complications of long-term levodopa therapy in Parkinson’s disease

B. Radojević, N. Dragašević-Mišković, A. Marjanović, A. Milovanović, M. Svetel, I. Petrović, M. Savić, I. Jančić, V. Kostić (Belgrade, Serbia)

Treatment characterization and decision-making strategy for first-line pharmacological motor symptomatic therapies in Parkinson’s disease

M. Javidnia, J. Jones, A. Ertefaie, C. Venuto (Rochester, NY, USA)

Vascular age calculated by pulse wave velocity may help predict the prognosis after Deep brain stimulation surgery in patients with Parkinson’s disease

N. Naoko, K. Matsuura, A. Shindou, H. Kajikawa, T. Araki, H. Tomimoto (Tsu, mie, Japan)

Vitamin D assessment in patents with Parkinson’s disease

N.A Mansurova, Y.N Madjidova (Tashkent, Uzbekistan)

« View all categories from the MDS Virtual Congress 2020.